Detailed Narrative
Strategic Pivot to High-Value Segments
Polymed is aggressively shifting its focus toward Cardiology, Critical Care, and Orthopedics to drive higher margins and import substitution. In Cardiology, the company sold over 4,000 stents in H1 and is conducting a 2,000-patient clinical study for its RisoR stent to enter Tier-1 hospitals. Management noted that these segments are currently 80-90% import-dependent in India, providing a significant domestic growth runway as they localize manufacturing.
European Acquisitions to Drive Synergies
The acquisition of Citieffe (Italy) and PendraCare (Netherlands) adds approximately ₹280 crores to the annual topline. While these entities currently operate at ~15% EBITDA margins, Polymed plans to improve this to 20%+ by leveraging its low-cost Indian manufacturing base for components. These acquisitions also provide a critical distribution footprint in Europe, helping to mitigate the 9.6% YoY degrowth seen in the region during Q2.
Domestic Market Outperformance
The domestic business remains the primary growth engine, with private sector revenue surging 22.3% in Q2. Polymed is deliberately scaling back its government business (which degrew 14%) due to low-margin L1 tender pricing. The company is expanding its frontline presence by hiring over 100 sales associates in FY26 to capture rising local demand, guiding for 28-30% domestic growth for the full year.
Navigating US Regulatory and Tariff Headwinds
The US market expansion faces significant friction due to a 50% tariff environment and a recent US FDA policy change rejecting Indian lab results. This has forced Polymed to restart product testing in US-based labs, delaying new approvals until mid-2026. Despite these challenges, management maintains a 3-year target of $15-$20 million for the US product pipeline, banking on a new IV catheter design expected to launch in Q4.
Capacity Expansion and Future Outlook
Polymed is investing over ₹250 crores in capex this year, with major facilities in Mitral and Haridwar (Phase-II) expected to be operational within 12-18 months. The company is also moving its planned Jaipur facility to a 7-acre plot in YEIDA near the new Jewar airport. These investments are designed to support the target of returning to 20% organic growth in the coming years as new product pipelines in Europe and the US mature.